March 3, 2026Open Access

A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2− breast cancer in China

Key Points

Abemaciclib showed consistent effectiveness in treating HR+/HER2- breast cancer, indicating a favorable benefit-risk profile.
Participants in the analysis included adults with early and advanced breast cancer who received abemaciclib for treatment.
This observational study evaluated the safety and tolerability of abemaciclib, validating its use in a real-world context.
The findings support the continued use of abemaciclib, emphasizing its positive real-world outcomes without new safety concerns.

Abstract

Real-world safety, tolerability, and effectiveness of abemaciclib in Chinese patients with HR+/HER2- EBC and ABC were consistent with clinical trials, with no new safety signals, supporting its positive real-world benefit-risk profile.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Ouyang et al. (Mon,) studied this question.

synapsesocial.com/papers/69a75b4ac6e9836116a22610 https://doi.org/https://doi.org/10.1093/oncolo/oyag013

Bookmark

View Full Paper